- Precigen Inc PGEN changed its exclusive license agreement with Alaunos Therapeutics (formerly known as Ziopharm Oncology Inc) to leverage the UltraCAR-T platform to develop and commercialize two CAR-T targets, CD19 and B-cell maturation antigen, to strengthen the portfolio and expand strategic opportunities.
- These targets extend Precigen’s UltraCAR-T library approach, which aims to transform the landscape of personalized cell therapy for cancer patients by developing and validating a library of non-viral plasmids to target various hematological and solid tumor-associated antigens.
- Precigen says the addition of CD19 and BCMA targets positions it as a leader in the CAR-T space.
- The company also regained exclusive rights to IL-12 gene therapy, including application through the AdenoVerse platform.
- The agreement eliminates all future royalties to Alaunos.
- In October 2018, Ziopharm scaled Support its alliance with Intrexon unit Precigen in oncology to focus on two immuno-oncology platforms.
- Last month, Precigen administered PRGN-3007 to the first patient in the Phase 1/1b dose escalation/expansion study in ROR1-positive (ROR1+) advanced patients. hematological and solid tumors.
- PRGN-3007 UltraCAR-T is an investigational multigene autologous CAR-T cell therapy.
- Price promotion: PGEN shares are down 6.70% to $1.05 on Tuesday’s latest check.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
